Registration:
To register for this activity, you will need an access code which can be found on the DOMTV webpage that corresponds with this activity. Click on the DOMTV Thumbnail/Graphic below, or click here to find the access code.
Description:
Dr. Antoni Ribas describes the development of immunotherapy for the treatment of advanced stage melanoma.
Speaker:
Antoni Ribas, MD Director of Tumor Immunology Program David Geffen School of Medicine at UCLA
Objectives:
At the conclusion of this activity, participants should be able to:
Accreditation:
The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement:
The FDA has issued a concept paper which classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is "truly independent" and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest from the CME staff and faculty be fully disclosed to the program's participants. In addition, policy of the Accreditation Council for Continuing Medical Education now mandates that the provider adequately manages all identified potential conflicts of interest prior to the program. We at UCLA fully endorse the letter and spirit of these concepts.
Disclosure Declaration:
Dr. Ribas has indicated that he does have an affiliation with organizations which may have interests related to the content of this program.
Dr. Ribas receives honoraria from consulting from Amgen, Chugai, Genentech, Merck, Novartis and Sanofi.
Dr. Ribas is on the scientific advisory board and owns stock in Advaxis, Arcus, Bioncotech, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, Isoplexis, Kite-Gilead, Merus, Regenix.
Dr. Ribas is the co-founder of and owns stock in Lutris, PACT Pharma, Tango Therapeutics.
Dr. Edward Lee and Joyce Fried have both indicated that they do not have affiliations with organizations which have interests related to the content of this program. This is pointed out to you so that you may form your own judgments about the presentation with full disclosure of the facts.
Instructions:
To earn credit for this activity, the participant must:
Cultural Competency:
With the passage of Assembly Bill 1195, physicians licensed in California must incorporate cultural competency and linguistics into their continuing medical education program of study.
To review an explanation of relevant federal and state laws and regulations regarding linguistic access, click here.
Click here for a list of cultural and linguistic competency resources.
